Publications - Search Publications by Mayo Clinic Authors - Mayo Clinic Research

no_english_version

no_arabic_version

Search

Request an Appointment
Find a Doctor
Find a Job
Give Now

Log in to Patient Account
English

Twitter
Facebook
Pinterest
YouTube

English

Menu
Search

Search

All Mayo Clinic Topics

Care at Mayo Clinic
Health Information
Featured conditions
Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
For Medical Professionals
Research
College of Medicine and Science
Giving to Mayo Clinic

Search Results 21-30 of 35 for bcg

Narrow your search

Year:

Results

A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
1. Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J.
2. Clin Cancer Res. 2023 Oct 2; 29 (19):3875-3881
Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non-Muscle-Invasive Bladder Cancer.
1. Weinberg MS, Zafar A, Magdamo C, Chung SY, Chou WH, Nayan M, Deodhar M, Frendl DM, Feldman AS, Faustman DL, Arnold SE, Vakulenko-Lagun B, Das S.
2. JAMA Netw Open. 2023 May 1; 6 (5):e2314336 Epub 2023 May 01
Impact of Bacillus Calmette-Guerin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection.
1. COVID Surg Collaborative.
2. BJS Open. 2021 Nov 9; 5 (6)
Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study.
1. Murakami K, Kamat AM, Dai Y, Pagano I, Chen R, Sun Y, Gupta A, Goodison S, Rosser CJ, Furuya H.
2. Cancer Biomark. 2022; 33 (1):151-157
Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.
1. Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ.
2. PLoS One. 2014; 9 (6):e96705 Epub 2014 June 04
Infection of an axillo-bifemoral bypass graft following intravesical bacillus Calmette-Guerin (BCG) immunotherapy for urothelial cancer due to Mycobacterium bovis and Staphylococcus aureus.
1. DeSimone DC, Tande AJ.
2. J Clin Tuberc Other Mycobact Dis. 2016 Dec; 5:1-3 Epub 2016 Sept 16
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.
1. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larre S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Gontero P.
2. World J Urol. 2018 Oct; 36 (10):1621-1627 Epub 2018 May 02
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
1. Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN.
2. Lancet Oncol. 2021 Jan; 22 (1):107-117 Epub 2020 Nov 27
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
1. Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD.
2. Nat Med. 2024 Aug; 30 (8):2372
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
1. Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD.
2. Nat Med. 2024 Aug; 30 (8):2377

Pagination Publications

Previous Page
Go to page 1
Go to page 2
Go to page 3
Go to page 4
Next Page

.

Mayo Clinic Footer

Request Appointment
Give Now
Contact Us
About Mayo Clinic
Employees
Site Map
About This Site

Legal Conditions and Terms

Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.

Terms and Conditions
Privacy Policy
Notice of Privacy Practices
Notice of Nondiscrimination
Manage Cookies

Advertising

Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.

Advertising and sponsorship policy
Advertising and sponsorship opportunities

Reprint Permissions

A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

© 1998-2025 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved.